Dexamethasone
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Dexamethasone: Alopecia mucinosa
One-Sentence Summary
Dexamethasone is a glucocorticoid with anti-inflammatory and immunosuppressive activity, marketed in Canada in many single-ingredient products. The TxGNN model predicts it may be effective for alopecia mucinosa, but no clinical trials and no publications currently support this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this drug. Dexamethasone is a corticosteroid, and glucocorticoids are generally used to dampen inflammatory and immune responses.
The high model score (0.9999) appears to reflect a shared hair-loss (alopecia) phenotype and proximity to related hair disorders in the model’s network. Any anti-inflammatory rationale for alopecia mucinosa is speculative, because no trials or literature were found that study this disease with dexamethasone. The prediction should therefore be regarded as a hypothesis only.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02204266 | DEXAMETHASONE-OMEGA | Not specified | Not specified |
| 02261081 | APO-DEXAMETHASONE | Not specified | Not specified |
| 01977547 | DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP | Not specified | Not specified |
| 02363445 | OZURDEX | Not specified | Not specified |
| 01946897 | PMS-DEXAMETHASONE ELIXIR | Not specified | Not specified |
The list above shows 5 of the licences in the local data, and the records may be partial. All listed licences are valid single-ingredient products.
Safety Considerations
- Drug Interactions: The interaction screening returned 100 interacting drugs. Major-level interactions include fentanyl and adalimumab. Moderate-level interactions include zidovudine, paclitaxel, abemaciclib, isotretinoin, acalabrutinib, acarbose, acebutolol, codeine, dihydrocodeine, acetazolamide, ketorolac, nifedipine and ibuprofen.
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone. No clinical trial or publication directly studies dexamethasone in alopecia mucinosa, so the evidence level is L5.
To proceed, the following is needed:
- Published case reports, case series or trials of corticosteroids in alopecia mucinosa
- Detailed mechanism of action data
- Package insert warnings and contraindications for the relevant formulation
- Assessment of the route of administration (topical, intralesional or systemic) suitable for the skin condition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.